Create New Account Purchaser Login
Search Tenders
Search
Advanced Search
You are not logged in.

Future Procurement Opportunity (FPO) – Supply of immune checkpoint inhibitors for the treatment of locally advanced/metastatic non-small cell lung cancer

Details

Tender Closed
RFx ID : 25820806
Tender Name : Future Procurement Opportunity (FPO) – Supply of immune checkpoint inhibitors for the treatment of locally advanced/metastatic non-small cell lung cancer
Reference # :
Open Date : Q2 2022
Indicative RFx Release Date  : Q3 2022  [?]
Tender Type : Future Procurement Opportunity (FPO)
Project Status : Awaiting approval  [?]
Indicative Total Value : $100M +  [?]
Tender Coverage : Sole Agency  [?]
Categories :
  • 51000000 - Drugs and Pharmaceutical Products
Regions:
  • New Zealand
Required Pre-qualifications : None
Contact : Pharmac Procurement Team
procurement@pharmac.govt.nz
.
Agency Address :
Related Tenders:
Overview

Pharmac will issue a competitive process for supply of immune checkpoint inhibitors (ICI’s) for the treatment of locally advanced/metastatic non-small cell lung cancer (NSCLC).

The anticipated outcome is a scenario where one or more ICI products would be awarded a period of Principal Supply exclusivity for listing in the Pharmaceutical Schedule, for one or more of the predefined patient groups; patients receiving ICIs for:
- first line 1L monotherapy;
- first line 1L combination therapy;
- second line 2L therapy.

RFx Outcome

This tender has been completed.

Date RFx was completed/updated: Wednesday, 13 July 2022 4:07 PM (Pacific/Auckland UTC+12:00)